SGO

AnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survival for the treatment of primary advanced or recurrent

Retrieved on: 
Monday, March 27, 2023
GSK, Society, SGO, Therapy, The New England Journal of Medicine, ESMO, Clinical trial, European Society for Medical Oncology, Gynecologic Oncology (journal), Society of Gynecologic Oncology, Oncology, Research, Part, Lung cancer, Endometrial cancer, HIV disease progression rates, Patient, Standard of care, Risk, SAN, Ovarian cancer, Death, Safety, Pharmaceutical industry, Dostarlimab

“We continue to be encouraged in the differentiated outcomes delivered by immuno-oncology antibodies discovered at AnaptysBio as GSK advances their development to treat multiple advanced solid tumors.

Key Points: 
  • “We continue to be encouraged in the differentiated outcomes delivered by immuno-oncology antibodies discovered at AnaptysBio as GSK advances their development to treat multiple advanced solid tumors.
  • The positive results from the RUBY trial represent a potential breakthrough for patients with primary advanced or recurrent endometrial cancer,” said Daniel Faga, interim president and chief executive officer of AnaptysBio.
  • Jemperli was discovered by AnaptysBio and licensed to TESARO, Inc., now a part of the GSK group of companies, under a Collaboration and Exclusive License Agreement signed in March 2014.
  • In 2021, AnaptysBio monetized with Sagard Healthcare Royalty Partners certain commercial milestones and royalties for annual net sales of Jemperli below $1 billion up to a certain amount of receivables before such receivables revert back to AnaptysBio.

KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma, Regardless of Mismatch Repair Status

Retrieved on: 
Monday, March 27, 2023
Biotechnology, General Health, Health, Pharmaceutical, Oncology, MSD, PMMR 62, The New England Journal of Medicine, SGO, Progression-free survival, Society of Gynecologic Oncology, Cancer, MRK, Paclitaxel, Gynecologic Oncology (journal), Carboplatin, PFS, HIV disease progression rates, Patient, Risk, Death, NYSE, Pharmaceutical industry, Merck

Results from the trial showed the KEYTRUDA regimen demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for patients, regardless of mismatch repair status.

Key Points: 
  • Results from the trial showed the KEYTRUDA regimen demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for patients, regardless of mismatch repair status.
  • Grade 3-5 adverse events (AEs) occurred in 55.1% of patients receiving the KEYTRUDA regimen and 45.3% of patients receiving chemotherapy alone in the pMMR cohort.
  • In the dMMR cohort, Grade 3-5 AEs occurred in 63.3% of patients receiving the KEYTRUDA regimen and 47.2% of patients receiving chemotherapy alone.
  • In endometrial cancer, Merck is evaluating KEYTRUDA in first-line advanced endometrial cancer both as monotherapy (KEYNOTE-C93/ENGOT-en15/GOG-3064) and in combination with LENVIMA (LEAP-001/ENGOT-en9), as well as in the adjuvant setting (KEYNOTE-B21/ENGOT-en11/GOG-3053).

Agenus’ Botensilimab in Combination with Balstilimab Shows 33% Durable Responses in Ovarian Cancer

Retrieved on: 
Monday, March 27, 2023
Biotechnology, Infectious Diseases, Health, Clinical Trials, Oncology, Inc., Society, SGO, Beth Israel Deaconess Medical Center, Infection, Cancer, Platinum, SITC, Gynecologic Oncology (journal), Society of Gynecologic Oncology, NSCLC, Biomarker, Publication, Lung cancer, Immunotherapy, Harvard Medical School, Patient, Colorectal cancer, Melanoma, Ovarian cancer, Conference, ORR, Safety, Vaccine, Mineral wool

These findings, presented in an oral plenary session at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer, showed a 33% overall response rate (ORR).

Key Points: 
  • These findings, presented in an oral plenary session at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer, showed a 33% overall response rate (ORR).
  • “The remarkable efficacy and manageable tolerability profile of this combination suggest a transformative potential for ovarian cancer patients.”
    The ovarian cancer cohort is part of a large study evaluating the safety, efficacy, and dose optimization of botensilimab alone and in combination with balstilimab in multiple solid tumors.
  • Agenus is currently enrolling in Global Phase 2 ACTIVATE trial programs in metastatic microsatellite stable colorectal cancer , melanoma and pancreatic cancers .
  • A total of 24 evaluable patients with recurrent platinum resistant/refractory ovarian cancer received either 1 or 2 mg/kg botensilimab every 6 weeks and 3 mg/kg balstilimab every 2 weeks.

ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting

Retrieved on: 
Saturday, March 25, 2023
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, Sequence, Bevacizumab, Society, SGO, Survival, Cancer, Gynecologic Oncology (journal), Mirvetuximab soravtansine, Society of Gynecologic Oncology, ImmunoGen, IMGN, Annual general meeting, Spacecraft, Pharmaceutical industry, Medical imaging, Patient

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced final overall survival data and an evaluation of sequence of therapy in the pivotal SORAYA trial of mirvetuximab soravtansine in patients with folate receptor alpha-high platinum-resistant ovarian cancer who had been previously treated with bevacizumab will be presented by Dr. Robert Coleman in a plenary session on Saturday, March 25, at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting in Tampa, Florida.

Key Points: 
  • ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced final overall survival data and an evaluation of sequence of therapy in the pivotal SORAYA trial of mirvetuximab soravtansine in patients with folate receptor alpha-high platinum-resistant ovarian cancer who had been previously treated with bevacizumab will be presented by Dr. Robert Coleman in a plenary session on Saturday, March 25, at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting in Tampa, Florida.
  • Title: Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Evaluation of Sequence of Therapy on Anti-Tumor Activity in the SORAYA Study

Aadi Bioscience Presents Clinical Data from PRECISION 1 and AMPECT Trials at the Society of Gynecological Oncology (SGO) Annual Meeting on Women's Cancer

Retrieved on: 
Sunday, March 26, 2023
Abstract (summary), Society, SGO, Society of Gynecologic Oncology, Woman, Research, AADI, Cancer, Patient, Oncology nursing, Pharmaceutical industry, Birth control, MD

LOS ANGELES, March 26, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that it presented data from its PRECISION 1 and AMPECT trials in two posters at the Society of Gynecological Oncology (SGO) Annual Meeting 2023, taking place March 25-28, 2023, in Tampa, FL.

Key Points: 
  • LOS ANGELES, March 26, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that it presented data from its PRECISION 1 and AMPECT trials in two posters at the Society of Gynecological Oncology (SGO) Annual Meeting 2023, taking place March 25-28, 2023, in Tampa, FL.
  • "We are pleased to present additional data with nab-sirolimus from our AMPECT trial and highlight our PRECISION 1 trial at SGO 2023, which is the premier medical meeting focused on advancing research for gynecologic cancer," said Loretta Itri, MD., Chief Medical Officer of Aadi Bioscience.
  • The details of the poster presentations are below:
    Title: "Response to treatment with nab-sirolimus among patients with primary uterine PEComa: A sub analysis from AMPECT"
    The Society of Gynecological Oncology Annual Meeting on Women's Cancer is the premier educational and scientific event for those who treat and care for women with gynecologic cancer.
  • Abstracts and full session details are available through the SGO Annual Meeting planner: Annual Meeting on Women's Cancer | SGO .

Eisai to Present Research from Oncology Portfolio at The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer

Retrieved on: 
Friday, March 24, 2023
MSD, Apoptosis, Abstract, Society, SGO, Senior, Gynecologic Oncology (journal), Society of Gynecologic Oncology, Research, Science, Eisai, LEAP, Patient, Merck, Merck & Co., FDA, Safety, Pharmaceutical industry

As a human health care company, we remain steadfast in our commitment to advance the science of cancer medicine through the generation of real-world evidence."

Key Points: 
  • As a human health care company, we remain steadfast in our commitment to advance the science of cancer medicine through the generation of real-world evidence."
  • To date, more than 10 trials have been initiated under the LEAP clinical program, which is evaluating the combination across multiple tumor types.
  • This release discusses investigational compounds and investigational uses for FDA-approved products.
  • There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.

Avenge Bio Announces Presentations at Two Key Upcoming Annual Conferences

Retrieved on: 
Wednesday, March 22, 2023
Society, AACR, SGO, Tampa Convention Center, Ovary, Biotechnology, American Association for Cancer Research, Gynecologic Oncology (journal), Cell, Immunotherapy, FL, Lung, Society of Gynecologic Oncology, The Company, Section 46 of the Constitution of Australia, Patient, Cancer, Reproductive toxicity, Ovarian cancer, Pharmaceutical industry, Vaccine, Fireworks

AVB-001, developed in the LOCOcyte™ platform, consists of proprietary engineered allogeneic human cells.

Key Points: 
  • AVB-001, developed in the LOCOcyte™ platform, consists of proprietary engineered allogeneic human cells.
  • The cells are encapsulated in a pro-inflammatory biomaterial that are delivered to the local tumor environment and generate high, sustained concentrations of human IL-2.
  • The product initiates a robust and durable, local and systemic immune response while avoiding toxicities associated with systemic immunotherapies.
  • Avenge has additional pipeline candidates for the treatment of a wide range of cancers including pancreatic, lung and breast cancers.

Agenus to Present Botensilimab Data in Oral Plenary Session at the Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer

Retrieved on: 
Tuesday, February 28, 2023
Society, Cancer, Patient, Immune system, Ovarian cancer, Annual general meeting, Publication, Infection, Gynecologic Oncology (journal), Conference, SGO, Society of Gynecologic Oncology, Platinum, Pharmaceutical industry

LEXINGTON, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Agenus (Nasdaq: AGEN), a clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, today announced plans to present updated data on its lead program botensilimab (Fc-enhanced anti-CTLA-4), at the Society of Gynecologic Oncology (SGO) 37th Annual Meeting on Women’s Cancer, to be held March 25-28 in Tampa, FL.

Key Points: 
  • LEXINGTON, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Agenus (Nasdaq: AGEN), a clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, today announced plans to present updated data on its lead program botensilimab (Fc-enhanced anti-CTLA-4), at the Society of Gynecologic Oncology (SGO) 37th Annual Meeting on Women’s Cancer, to be held March 25-28 in Tampa, FL.
  • Updated data from an expansion cohort of the Phase 1 study of botensilimab in combination with balstilimab (anti-PD-1) in patients with recurrent platinum refractory/resistant ovarian cancer will be presented at an oral plenary session on Monday, March 27th at 9:18am ET.
  • Abstract Title: Botensilimab, a Novel Innate/Adaptive Immune Activator, plus Balstilimab (Anti-PD-1) in Patients with Recurrent Platinum Refractory/Resistant Ovarian Cancer (NCT03860272)
    The complete abstract will be available the morning of the presentation at 9:00am ET.
  • Data presented at the conference will be available to view in the Publications section of the Agenus website ( https://agenusbio.com/publications ) following the SGO Conference.

ImmunoGen Reports Recent Progress and Third Quarter 2022 Financial Results

Retrieved on: 
Friday, November 4, 2022
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Society, Bevacizumab, Ovarian cancer, FDA, PIN, Zenith Contract Services, Research, ImmunoGen, U.S. Securities and Exchange Commission, Clinical trial, Lilly, Oncology, Capital expenditure, National Comprehensive Cancer Network, Society of Gynecologic Oncology, Program, ESGO, Venetoclax, Company, Congress, BLA, Carboplatin, ASH, Gynecologic Oncology (journal), BPDCN, Journal of the National Comprehensive Cancer Network, PDUFA, Hematology-Oncology and Stem Cell Transplantation Research Center, Security (finance), IMGN, Control, Patient, Cancer, ADC, Maintenance, Azacitidine, ESMO, European Society of Gynaecological Oncology, COVID-19, Annual general meeting, Novartis, SOHO, NCCN, SGO, Acute myeloid leukemia, Standard of care, Risk, AML, György Enyedi (geographer), Vaccine, Pharmaceutical industry, Medical imaging, Platinum, Cryptocurrency

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2022.

Key Points: 
  • ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2022.
  • With an intense focus on execution, we are well positioned to transform ImmunoGen into a fully-integrated oncology company this year.
  • Total revenues were $15.4 million for the quarter ended September 30, 2022 compared to $9.2 million for the quarter ended September 30, 2021.
  • Operating expenses for the quarter ended September 30, 2022 were $92.8 million, compared with $43.4 million for the same quarter in 2021.

SONORO GOLD ENGAGES SRK CONSULTING TO UPDATE MINERAL RESOURCE ESTIMATE AT CERRO CALICHE GOLD PROJECT

Retrieved on: 
Tuesday, November 1, 2022
CEO, Mineral resource estimation, SGO, GLOBE, Board, Gold, Technical report, Company, Record, Mining, MRE, Solution, Uranium

VANCOUVER, Canada, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Sonoro Gold Corp. (TSXV: SGO | OTCQB: SMOFF | FRA: 23SP) (Sonoro or the Company) is pleased to announce the Company has engaged SRK Consulting (U.S.), Inc. to prepare an NI 43-101 compliant updated Mineral Resource Estimate (MRE) for the Cerro Caliche gold project in Sonora, Mexico.

Key Points: 
  • VANCOUVER, Canada, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Sonoro Gold Corp. (TSXV: SGO | OTCQB: SMOFF | FRA: 23SP) (Sonoro or the Company) is pleased to announce the Company has engaged SRK Consulting (U.S.), Inc. to prepare an NI 43-101 compliant updated Mineral Resource Estimate (MRE) for the Cerro Caliche gold project in Sonora, Mexico.
  • The resource estimate is being updated now in connection with our on-going work to secure project financing, said Sonoros President and CEO, Kenneth MacLeod.
  • We continue to successfully proceed through the environmental permitting phase to facilitate our primary strategy of launching Cerro Caliche into production.
  • Sonoro Gold Corp. is a publicly listed exploration and development Company holding the near-development-stage Cerro Caliche project and the exploration-stage San Marcial project in Sonora State, Mexico.